SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Netanyahu’s lead in Israel’s vote count leaves both camps short of power

“The initial results indicate a complete vote of no confidence in Netanyahu”: Eisenkot vows to replace PM

Israel faces political deadlock as Netanyahu and opposition set to struggle to form a government

Netanyahu’s Likud emerges as Israel’s largest party, but exit polls point to another political deadlock

Buzz

Most popular

Daily

Weekly

1

Microsoft offers buyouts to 60,000 workers but says layoffs remain an option

2

Intel to acquire Israeli quantum startup Classiq for $2.3 billion

3

Intel’s $2.3 billion Classiq deal follows years of personal investment by Lip-Bu Tan

4

Classiq founders set to pocket up to $100 million each in Intel’s $2.3 billion deal

5

Palantir CEO says Israel is the "minor exception" in AI race dominated by U.S. and China

Richard Francis

8 stories about Richard Francis

בניין חברת טבע בכפר סבא לצד מנכ"ל טבע ריצ'רד פרנסיס

Teva’s comeback is real. The harder part is still ahead

22.09.26|Sophie Shulman

The company has cleaned up its balance sheet and rebuilt its pipeline, but investors are still waiting to see whether the new strategy can deliver sustained growth.

ריצרד פרנסיס נשיא ו מנכל טבע

Teva’s $40 billion comeback brings Wall Street’s biggest prize into view

30.07.26|Sophie Shulman

After years as a struggling generic-drug giant, Teva’s transformation under Richard Francis has pushed its valuation above $40 billion and raised the possibility of joining the S&P 500.

בניין חברת טבע כפר סבא

The deal that signals Teva is back

30.04.26|Sophie Shulman

A calculated biotech acquisition and strong earnings revive confidence in the pharma giant.

ריצ'רד פרנסיס מפגש העיתונאים

Teva CEO cashes in $30 million in shares in two weeks

08.03.26|Sophie Shulman

Richard Francis sells stock after Teva’s 110% rally over the past year.

נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman

Innovative drugs surge, but 2026 forecasts revive investor doubts.

מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman

Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.

ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman

Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.

מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman

Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory